Medwise.ai vs OpenEvidence (2026)
Two clinical search products built for different accountability structures. Medwise is built for a national health service, with its corpus assembled and governed against that institution's own guidance, which matters because clinicians there are judged against national standards rather than against the primary literature. OpenEvidence answers from current published evidence through partnerships with major journals, is free to verified clinicians and carries the deepest independent evaluation literature in this category. The divergence between national guidance and the latest literature is real and neither vendor dwells on it. Inside that health service, answering from the guidance you are accountable to is the safer position. Outside it, OpenEvidence has far more external scrutiny behind it, and its advertising funded model is the thing to weigh.
- It is built for one national health service, with the corpus assembled and governed to that institution's requirements rather than to a general market.
- Its platform terms carry a published statement about the limits of the answers that is unlike anything else in this category.
- For an organisation inside that health service, a product configured to its own guidance is closer to the standard clinicians are held to than a global corpus.
- The independent literature is the deepest in this category, with a systematic review identifying eleven studies evaluating the product across two years.
- Named partnerships with major journals and a systematic review publisher supply current primary literature rather than a national guidance set.
- It is free to verified clinicians with native mobile applications and enterprise record system embedding at named health systems.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Medwise.ai and OpenEvidence are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Medwise.ai | OpenEvidence |
|---|---|---|
| Primary category | Clinical Reference & Evidence | Clinical Reference & Evidence |
| Founded | 2019 | 2021 |
| Headquarters | Leeds, England | Miami, Florida |
| Website | medwise.ai | openevidence.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index records no top capability grade for Medwise.ai on any axis it scores. Set against OpenEvidence, Medwise.ai grades higher on FDA and Regulatory Status. Its thinnest published disclosure sits on AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards OpenEvidence its top capability grade on AI Centrality and Security Certifications and Trust Center. Set against Medwise.ai, OpenEvidence grades higher on several axes, including AI Centrality, Clinical and Operational Evidence and AI Safety and PHI Stewardship. Its thinnest published disclosure sits on AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Medwise.ai or OpenEvidence?
On the axes where the AI Health Index separates them, Medwise.ai grades higher on FDA and Regulatory Status, and OpenEvidence grades higher on several axes, including AI Centrality, Clinical and Operational Evidence and AI Safety and PHI Stewardship. OpenEvidence leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Medwise.ai and OpenEvidence differ most?
The widest separation the AI Health Index records between Medwise.ai and OpenEvidence is on AI Centrality, where Medwise.ai grades C and OpenEvidence grades A. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Medwise.ai and OpenEvidence grade the same?
The AI Health Index grades Medwise.ai and OpenEvidence the same on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Medwise.ai and OpenEvidence not disclosed?
At the last review, at least one of Medwise.ai and OpenEvidence published thin or absent detail on AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
These are built for different evidentiary cultures and the comparison should not be run on breadth: one answers from national guidance a clinician is accountable to, the other from the primary literature, and those diverge more often than either vendor acknowledges.
OpenEvidence is funded by pharmaceutical and device advertising displayed alongside clinical answers, governed by a published policy that should be read before deployment in any setting where that relationship would be unacceptable. Medwise publishes no security certification, no verified record system integration and a commercial account that has been inconsistent across time. Neither publishes an accuracy figure.